News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
587,472 Results
Type
Article (19238)
Company Profile (176)
Press Release (568056)
Multimedia
Podcasts (81)
Webinars (13)
Section
Business (198510)
Career Advice (702)
Deals (30779)
Drug Delivery (105)
Drug Development (65725)
Employer Resources (55)
FDA (12430)
Job Trends (11116)
News (288037)
Policy (24151)
Tag
2025 Best Places to Work (8)
2026 Best Places to Work (16)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (1)
40 Under 40 (2)
Academia (842)
Accelerated approval (53)
ADA (26)
Adcomms (10)
Allergies (157)
Alliances (41817)
ALS (164)
Alzheimer's disease (1326)
Antibody-drug conjugate (ADC) (444)
Approvals (13202)
Artificial intelligence (606)
ASCO (221)
Autoimmune disease (326)
Automation (48)
Bankruptcy (322)
Belgium (9)
Best Places to Work (8366)
BIO (49)
Biologics (83)
BIOSECURE Act (10)
Biosimilars (218)
BioSpace Insights (82)
Biotechnology (104)
Bispecific (31)
Bladder cancer (167)
Brain cancer (66)
Breast cancer (662)
Cancer (5074)
Cardiovascular disease (403)
Career advice (613)
Career pathing (15)
CAR-T (248)
CDC (11)
CDMO (113)
Celiac Disease (4)
Cell therapy (684)
Cervical cancer (46)
Clinical research (59827)
Collaboration (1915)
Commercialization (52)
Company closure (3)
Compensation (1693)
Complete response letters (64)
COVID-19 (1311)
CRISPR (95)
CRO (2)
C-suite (1248)
Cystic fibrosis (131)
Data (7892)
Decentralized trials (2)
Denatured (23)
Depression (133)
Dermatology (126)
Diabetes (507)
Diagnostics (4959)
Digital health (51)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (305)
Drug pricing (130)
Drug shortages (16)
Duchenne muscular dystrophy (251)
Earnings (82305)
Editorial (25)
Employer branding (5)
Employer resources (51)
ESMO (279)
Events (101075)
Executive appointments (1036)
Eye disease (9)
FDA (16033)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (4)
Friedreich's ataxia (24)
Frontotemporal dementia (31)
Funding (1367)
Gene editing (181)
Generative AI (44)
Gene therapy (515)
GLP-1 (722)
Government (2034)
Grass and pollen (5)
Guidances (339)
Healthcare (11180)
Hematology (149)
HIV (63)
Huntington's disease (37)
Idiopathic pulmonary fibrosis (7)
IgA nephropathy (123)
Immunology and inflammation (189)
Immuno-oncology (100)
Indications (238)
Infectious disease (1574)
Inflammatory bowel disease (195)
Inflation Reduction Act (9)
Influenza (105)
Intellectual property (325)
Interviews (93)
IPO (13997)
IRA (33)
Job creations (3105)
Job search strategy (552)
JPM (29)
Kidney cancer (23)
Kidney disease (123)
Labor market (48)
Layoffs (262)
Leadership (14)
Legal (6583)
Licensing (96)
Liver cancer (58)
Longevity (39)
Lung cancer (734)
Lung diease (13)
Lymphoma (383)
Machine learning (38)
Management (19)
Manufacturing (1093)
Marketing (35)
MASH (183)
Medical affairs (4)
Medical device (9336)
Medtech (9550)
Mergers & acquisitions (18086)
Metabolic disorders (1197)
Middle East (1)
mRNA (146)
Multiple sclerosis (159)
Multispecific (4)
NASH (15)
Netherlands (8)
Neurodegenerative disease (341)
Neuropsychiatric disorders (79)
Neuroscience (2659)
Neurotech (3)
NextGen: Class of 2026 (3895)
Non-profit (1261)
Now hiring (29)
Obesity (474)
Opinion (162)
Ovarian cancer (206)
Pain (280)
Pancreatic cancer (270)
Parkinson's disease (305)
Partnered (24)
Patents (653)
Patient advocacy (4)
Patient recruitment (654)
Patient selection (70)
Peanut (43)
People (51190)
Peptides (31)
Pharmaceutical (46)
Pharmacy benefit managers (26)
Phase 1 (18421)
Phase 2 (26334)
Phase 3 (19575)
Pipeline (10884)
Policy (178)
Postmarket research (2126)
Preclinical (7632)
Press Release (49)
Prostate cancer (262)
Psychedelics (40)
Radioligand (1)
Radiopharmaceuticals (298)
Rare diseases (967)
Real estate (4470)
Recruiting (20)
Regenerative medicine (21)
Regulatory (20321)
Reports (36)
Research institute (975)
Resumes & cover letters (94)
Rett syndrome (50)
RNA editing (16)
RSV (57)
Saudi Arabia (1)
Schizophrenia (164)
Series A (257)
Series B (167)
Service/supplier (5)
Sickle cell disease (108)
Special edition (15)
Spinal muscular atrophy (119)
Sponsored (17)
Startups (2792)
State (2)
Stem cells (4)
Stomach cancer (10)
Substance use disorders (18)
Supply chain (105)
Switzerland (13)
Tariffs (73)
The Weekly (56)
Vaccines (564)
Venture capital (67)
Weight loss (247)
Wet AMD (3)
Women's health (128)
Worklife (5)
Date
Last 7 days (719)
Last 30 days (2641)
Last 365 days (23313)
2026 (21089)
2025 (23301)
2024 (27244)
2023 (31376)
2022 (40748)
2021 (43345)
2020 (39855)
2019 (29680)
2018 (22622)
2017 (24682)
2016 (23531)
2015 (29424)
2014 (25670)
2013 (22071)
2012 (24094)
2011 (24438)
2010 (23670)
Location
Africa (474)
Alabama (90)
Alaska (2)
Arizona (370)
Arkansas (14)
Asia (30513)
Australia (4199)
California (14165)
Canada (3795)
China (1202)
Colorado (583)
Connecticut (535)
Delaware (311)
Europe (55329)
Florida (2155)
Georgia (455)
Hawaii (3)
Idaho (49)
Illinois (969)
India (123)
Indiana (616)
Iowa (21)
Japan (653)
Kansas (123)
Kentucky (42)
Louisiana (35)
Maine (29)
Maryland (1504)
Massachusetts (9720)
Michigan (344)
Minnesota (672)
Mississippi (6)
Missouri (110)
Montana (27)
Nebraska (16)
Nevada (142)
New Hampshire (69)
New Jersey (3584)
New Mexico (18)
New York (3452)
North Carolina (1682)
North Dakota (4)
Northern California (7203)
Ohio (343)
Oklahoma (18)
Oregon (31)
Pennsylvania (2671)
Puerto Rico (31)
Rhode Island (39)
South America (733)
South Carolina (86)
South Dakota (1)
Southern California (5870)
Tennessee (159)
Texas (2316)
United States (47809)
Utah (435)
Vermont (1)
Virginia (299)
Washington D.C. (52)
Washington State (1087)
West Virginia (2)
Wisconsin (125)
Wyoming (2)
587,472 Results for "agios pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Agios axes 100-plus R&D roles while awaiting FDA decision
After the FDA delayed a decision for Agios Pharmaceuticals’ sickle cell disease candidate, the biopharma is letting go of more than 35% of its R&D employees.
November 6, 2026
·
2 min read
·
Gabrielle Masson
Sickle cell disease
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
July 21, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
November 5, 2026
·
12 min read
Press Releases
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
October 8, 2026
·
2 min read
Press Releases
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
·
13 min read
Press Releases
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
October 30, 2026
·
15 min read
Press Releases
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
November 4, 2026
·
15 min read
Press Releases
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
July 21, 2026
·
7 min read
Press Releases
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
July 7, 2026
·
15 min read
Press Releases
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
May 24, 2026
·
15 min read
1 of 58,748
Next